ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power DemandTransaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy storage solutionsOctober 01, 2025 8:30 AM EDT | Source: Entero Therapeutics, Inc.Boca Raton, Florida--(Newsfile Corp. - October 1, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("ENTO" or ...

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Entero Therapeutics, Inc. is included in them. Entero Therapeutics, Inc. (NASDAQ:ENTO) is a clinical-stage biopharmaceutical company developing targeted, non-systemic therapies for gastrointestinal disorders, including celiac disease, gastroparesis, and pancreatic insufficiency. The company has recently drawn attention as a biotech penny stock due to key developments in September 2025. A major change in ...

Richard Paolone, the Company's Interim Chief Executive Officer, commented, "The reverse split is a necessary step in our efforts to maintain our listing on the Nasdaq market. The visibility and credibility that comes with a Nasdaq listing is an important component in our efforts to enhance shareholder value." Boca Raton, Florida--(Newsfile Corp. - August 14, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targete ...